The long-awaited first single-dose vaccine began early this Wednesday to be distributed among the autonomous communities. There were 146,000 vials that had arrived in Spain last week but that Janssen herself had retained in its warehouses until on Tuesday the European Medicines Agency (EMA) again gave its endorsement of the safety of this prophylaxis after analyzing the eight cases of thrombosis recorded among seven million people who had received the Johnson & Johnson formula in the United States and conclude that these strokes are indeed linked to the vaccine, although the benefits of inoculation far outweigh the risks.
With this mantra, Health hopes to turn Janssen into the other mainstay of the short vaccination campaign, together with Pfizer, to ensure that on August 31, 70% of the country’s population (33 million people) is immunized with the full dose. The advantage of the Janssen formula of relying on a single puncture will undoubtedly speed up the process. But above all, also, the promises of supplies in exponential growth. According to the agreements closed with the laboratory, 300,000 injectables should arrive this April. During May and June it should be about 4.7 million more. And between July and September the company should serve Health about 12.5 million.
The contract with Janssen, according to official Health documents, is that by the end of the third semester the laboratory must have delivered 17,598,400 to Spain. In other words, there would be enough doses from this laboratory to immunize more than a third of Spain. Only Pfizer / BionTech, among the other brands already authorized by the EMA, as 43,955,845 doses committed until September would exceed the potential of Janssen, since these vials will serve to immunize about 22 million people.
But Johnson & Johnson’s prophylaxis will not be able to be distributed as widely as Health would like to increase the rate of vaccination on account of the single doses. Clot problems in women between 18 and 48 years old detected in the United States, in principle, will make it unlikely that Health will authorize the use of Janssen in a population below, at least, 50 years.
The formula that is now reserved for the group between 70 and 79 years old – they explain in the Vaccine Report – could be extended to other younger age groups “depending on the needs and supplies”, but not to young adults, young people, adolescents and children, so Janssen, beyond summer, is not expected to remain one of the main pillars of the campaign as if it will be at least until herd immunity is achieved with that 70% of the population vaccinated with full guideline.
Thus, they admit from Health, the Janssen vials would be the perfect candidates, probably with those of AstraZeneca that are also banned to those under 60 years of age, to be sent from the summer to third countries within the delivery plan that the Government it is finalizing with Latin American states and in coordination with the European Union.
#Health #Janssen #singledoses #immunize #Spain